Homburger | View firm profile
On May 27, 2025, BeOne Medicines Ltd., a global oncology company, officially completed its redomiciliation from the Cayman Islands to Basel, Switzerland, following shareholder approval on April 28, 2025.
The redomiciliation to Switzerland strengthens BeOne’s presence and deepens its roots in a global biopharmaceutical hub, further enabling its growth strategy of bringing innovative medicines to patients around the world.
BeOne Medicines Ltd.’s American Depositary Shares are listed on the Nasdaq Global Select Market, each representing 13 ordinary shares of BeOne Medicines Ltd., each having a par value of USD 0.0001 per share (the “Ordinary Shares”), the Ordinary Shares are listed on The Stock Exchange of Hong Kong Limited, and the Ordinary Shares traded in Renminbi are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.
The Homburger team was led by David Oser (Corporate / M&A, Capital Markets) and included Bianca Nedwed and Kaiyan Yeo (both Corporate / M&A, Capital Markets), Stefan Bindschedler and Benjamin Leisinger (Banking and Finance) as well as Stefan Oesterhelt and Juliette Buob (both Tax).
Contact
Johanna Schmid / Marketing / [email protected]